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follow-up was 35 months (range 7–71). Two-year and ﬁve-year overall survival (OS) and cause-speciﬁc survival (CSS) were 55%
and 20%, 66% and 33% respectively.
Conclusions. In our series conservative treatment with radiochemotherapy in locally advanced oral cavity cancer offers a good
toxicity proﬁle and results comparable to those published in the literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.258
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Purpose. The aim of this study is to describe compliance, acute toxicity and radiochemotherapy treatment outcomes in patients
diagnosed with locally advanced squamous cell carcinoma of oropharynx.
Patients and methods. From March 2002 to January 2012, 44 patients diagnosed with locally advanced oropharynx cancer were
treated in our department with chemoradiation therapy with radical intention. The radiotherapy schedule used was 50Gy to
clinical target volume (CTV) and 70Gy to the gross target volume (GTV). The concomitant chemotherapy (QT) regimens were
adapted to each clinical case.
Results. The median age was 57 years (range 39–84), 84% male and 16% female. 20% of all patients were stage III and 80% stage
IV. 75% of all patients received concomitant QT according to the following schemes: 51% received weekly CDDP, 17% CDDP every
21 days, 12% carboplatin, cetuximab 10% and the remaining patients received others regimens. G3 toxicity was seen in 49%
of patients and mucositis and epitelitis were the most frequent. Median follow-up was 24 months (range 4–63). Two-year and
ﬁve-year overall survival (OS), cause-speciﬁc survival (CSS) and disease-free survival (DFS) were 50% and 28%, 56% and 51%, 49%
and 37%, respectively. There was not signiﬁcant difference in survival with the following analyzed variables: sex, age and QT
scheme.
Conclusions. In our series conservative treatment with radiochemotherapy in locally advanced oropharynx cancer offers a good
toxicity proﬁle and results comparable to those published in the literature.
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Summary. Hemangiopericytoma is an uncommon mesenchymal neoplasm arising from Zimmerman’s pericytes, which usually
locates in soft tissues. Meningeal hemangiopericytoma accounts for less than 1% of all intracranial tumours. Typically, it behaves
aggressively, showing distinct tendency to recur locally or distantly along the neural axis and to present extraneural metastases.
Objective. Review treatment of cranial hemangiopericytoma (HPC), conducting a literature review of the literature in Medline,
concerning two cases.
Method and results. A revision ismade inMedline, introducing like keywords “hemangiopericytoma” and “cranial fossa”, analyzing
the types of treatments published. It is decided to treat according to the published protocols. Oncology story 1: male 22 years,
who presents with nausea, epigastric discomfort accompanied by disconnection of the medium, stare, loss of consciousness
and generalized clonic movements with post-critical stupor. In MRI: glioneuronal lesion of slow growth. It operates through right
temporal craniotomy with surgical excision of the dural implantation site serving the greater wing of the sphenoid and temporal
muscle affected. AP: solitary ﬁbrous tumor with hemangiopericytoma-like pattern of WHO Grade II Receiving radiation therapy
(RT) adjuvant VMAT technique, 50Gy dose-based on the surgical fusion of images taken from brain MRI. Oncology story 2: male
38 years, debuting visual acuity of 2 months’ duration and temporal hemianopsia. CT and MRI IN: LOE anterior fossa suggestive
of olfactory groove meningioma. It operates through bifrontal craniotomy and tumor excision. AP: Solitary ﬁbrous tumor with
hemangiopericytoma-like pattern of WHO Grade II Adjuvant RT was administered (VMAT technique) 45Gy to the tumor bed level
with margin, reaching 50Gy to the tumor bed level.
Conclusion. In current clinical decision making regarding treatment of hemangiopericytoma is mainly based on retrospective
data. In literature, the practical approach is to give adjuvant RT dose of 50–60Gy. More research is clearly needed to determine
the optimal therapeutic strategy.
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